Salvage therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Marrow transplantation as salvage therapy in non-Hodgkin's lymphoma seems to be superior to chemotherapy administered in conventional doses, although trials are ongoing. Transplantation results are better when refractory and relapsed patients respond to conventional salvage therapy (sensitive relapse) and residual disease is reduced to a minimum. The authors summarize clinical findings to date, including the latest work with interferon and monoclonal antibodies.
Bierman
P
P
Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, California.
Armitage
J O
JO
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000473:pathology; D003131:Combined Modality Therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009367:Neoplasm Staging